Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$59.69 /

+0.26 (+0.44%)

07:23
08/06/20
08/06
07:23
08/06/20
07:23

Investors can refocus on Bristol-Myers story after Eliquis win, says Citi

The removal of the fear of early generic Eliquis entrants should enable investors to refocus on the underlying Bristol-Myers equity story, Citi analyst Andrew Baum tells investors in a research note. A Delaware judge yesterday ruled Bristol-Myers and Pfizer proved that generics would infringe on valid patents for the blood-thinner drug. Bristol's current valuation is "undemanding" with little value attribution to its earlier stage oncology assays, including the "expansive" immuno-oncology portfolio, contends Baum. The analyst was "relieved but not surprised" by yesterday's patent ruling and keeps a Buy rating on Bristol-Myers.

  • 06

    Aug

  • 06

    Aug

  • 17

    Aug

  • 03

    Sep

BMY Bristol-Myers
$59.69 /

+0.26 (+0.44%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers

TODAY'S FREE FLY STORIES

Initiation
Schroders initiated with an Underperform at RBC Capital » 21:12
09/28/20
09/28
21:12
09/28/20
21:12
SHNWF

Schroders

$0.00 /

+ (+0.00%)

RBC Capital analyst…

RBC Capital analyst Mandeep Jagnal initiated coverage of Schroders with an Underperform rating and 2,300 GBp price target. The company's business mix is the most negatively exposed to the trends of declining revenue margins and net outflows given that it has the highest proportion of actively managed assets under management at 91% of the total, the analyst tells investors in a research note.

ShowHide Related Items >><<
SHNWF Schroders
$0.00 /

+ (+0.00%)

08/03/20 Berenberg
Schroders price target raised to 3,200 GBp from 2,203 GBp at Berenberg
07/15/20 UBS
Schroders price target raised to 3,175 GBp from 2,950 GBp at UBS
07/09/20 Morgan Stanley
Schroders price target lowered to 2,610 GBp from 2,640 GBp at Morgan Stanley
06/25/20 Credit Suisse
Schroders downgraded to Underperform from Neutral at Credit Suisse
Upgrade
Estee Lauder upgraded to Neutral from Sell at Goldman Sachs » 21:08
09/28/20
09/28
21:08
09/28/20
21:08
EL

Estee Lauder

$215.58 /

+0.15 (+0.07%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

09/04/20 Raymond James
Estee Lauder price target raised to $235 from $210 at Raymond James
09/03/20 Morgan Stanley
Brown-Forman price target raised to $66 from $56 at Morgan Stanley
08/26/20 Argus
Estee Lauder price target raised to $240 from $220 at Argus
08/24/20
Fly Intel: Top five analyst upgrades
EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

EL Estee Lauder
$215.58 /

+0.15 (+0.07%)

Initiation
Wizz Air initiated with an Outperform at Bernstein » 21:00
09/28/20
09/28
21:00
09/28/20
21:00
WZZAF

Wizz Air

$0.00 /

+ (+0.00%)

Bernstein analyst Daniel…

Bernstein analyst Daniel Roeska initiated coverage of Wizz Air with an Outperform rating and 4,500 GBp price target. The analyst expects the company to emerge as a "clear winner" from the COVID-19 pandemic, calling the company the "last great growth story" in European aviation. Roeska states that Wizz Air has a "structural" growth runway for "at lease a decade" thanks to its efficient cost structure, balance sheet, and order book. The analyst adds that the company would be able to add more than 70% of its growth without "overwhelming the market".

ShowHide Related Items >><<
WZZAF Wizz Air
$0.00 /

+ (+0.00%)

09/23/20 Morgan Stanley
Wizz Air price target raised to 4,500 GBp from 3,800 GBp at Morgan Stanley
07/31/20 Berenberg
Wizz Air price target raised to 4,200 GBp from 4,000 GBp at Berenberg
07/30/20 JPMorgan
Wizz Air price target raised to 4,200 GBp from 4,150 GBp at JPMorgan
07/30/20 UBS
Wizz Air price target raised to 3,385 GBp from 3,255 GBp at UBS
Initiation
Epiroc initiated with a Buy at Societe Generale » 20:54
09/28/20
09/28
20:54
09/28/20
20:54
EPOKY

Epiroc

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EPOKY Epiroc
$0.00 /

+ (+0.00%)

09/18/20 Berenberg
Epiroc initiated with a Buy at Berenberg
07/24/20 JPMorgan
Epiroc price target raised to SEK 115 from SEK 105 at JPMorgan
07/24/20 Deutsche Bank
Epiroc price target raised to SEK 120 from SEK 105 at Deutsche Bank
07/24/20 Credit Suisse
Epiroc price target raised to SEK 105 from SEK 88 at Credit Suisse
Initiation
GreenPower Motor initiated with a Buy at BTIG » 20:50
09/28/20
09/28
20:50
09/28/20
20:50
GP

GreenPower Motor

$10.91 /

-0.31 (-2.76%)

BTIG analyst Gregory…

BTIG analyst Gregory Lewis initiated coverage of GreenPower Motor with a Buy rating and $25 price target. The analyst calls the company a "rising star" in the EV bus market, with its EV Star flagship vehicle already having been deployed across municipalities and airports across California with roughly 90 EV Stars currently on the road. Following its recent up-listing to NASDAQ. Lewis contends that GreenPower is well-positioned in the medium-term to ramp vehicle production.

ShowHide Related Items >><<
GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

09/08/20 B. Riley FBR
GreenPower Motor initiated with a Buy at B. Riley FBR
09/02/20 Roth Capital
GreenPower Motor price target raised to $31 from $23.18 at Roth Capital
09/01/20 Roth Capital
GreenPower Motor price target raised to $31 from $23.18 at Roth Capital
GP GreenPower Motor
$10.91 /

-0.31 (-2.76%)

Initiation
Metso Outotec initiated with a Buy at Societe Generale » 20:46
09/28/20
09/28
20:46
09/28/20
20:46
OUKPY

Metso Outotec

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OUKPY Metso Outotec
$0.00 /

+ (+0.00%)

08/27/20 UBS
Metso Outotec price target raised to EUR 8.30 from EUR 6.20 at UBS
08/11/20 Morgan Stanley
Metso Outotec price target raised to EUR 6.90 from EUR 5.60 at Morgan Stanley
08/06/20 JPMorgan
Metso Outotec price target raised to EUR 8 from EUR 6.50 at JPMorgan
07/07/20 JPMorgan
Metso Outotec initiated with an Overweight at JPMorgan
Initiation
FLSmidth initiated with a Hold at Societe Generale » 20:43
09/28/20
09/28
20:43
09/28/20
20:43
FLIDF

FLSmidth

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Chand Debashis initiated coverage of FLSmidth with a Hold rating and DKK 210 price target. The analyst notes that the company's gradual shift toward being more mining focused is positive while offering a constructive outlook on the mining industry. Debashis adds however that the "challenging" cement market and FLSmidth's recent execution dampen his optimism.

ShowHide Related Items >><<
FLIDF FLSmidth
$0.00 /

+ (+0.00%)

08/31/20
Fly Intel: Top five analyst downgrades
08/31/20 Danske Bank
FLSmidth downgraded to Sell from Hold at Danske Bank
04/16/20 Credit Suisse
FLSmidth price target lowered to DKK 140 from DKK 207 at Credit Suisse
04/08/20 JPMorgan
FLSmidth price target lowered to DKK 205 from DKK 215 at JPMorgan
Hot Stocks
Salesforce CEO sells 30K shares of common stock » 20:33
09/28/20
09/28
20:33
09/28/20
20:33
CRM

Salesforce

$246.66 /

+3.95 (+1.63%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

09/18/20 Baird
Salesforce benefitting from pandemic ecommerce burst, says Baird
08/26/20 Morgan Stanley
Salesforce price target raised to $275 from $195 at Morgan Stanley
08/26/20 JPMorgan
Salesforce price target raised to $250 from $200 at JPMorgan
08/26/20 Monness Crespi
Salesforce price target raised to $275 from $195 at Monness Crespi
CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

CRM Salesforce
$246.66 /

+3.95 (+1.63%)

Upgrade
Henkel upgraded to Buy from Neutral at Goldman Sachs » 19:42
09/28/20
09/28
19:42
09/28/20
19:42
HENKY

Henkel

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Olivier Nicolai upgraded Henkel to Buy from Neutral with a price target of EUR 102, up from EUR 80. The company's long-term growth profile below its peers, but its current low expectations are achievable and the risk/reward on the stock is attractive given the current valuation, the analyst tells investors in a research note. Nicolai adds that Henkel's margin "reset" has already happened while the company's balance sheet also "remains solid".

ShowHide Related Items >><<
HENKY Henkel
$0.00 /

+ (+0.00%)

09/08/20 Morgan Stanley
Henkel price target raised to EUR 74 from EUR 69 at Morgan Stanley
08/26/20 RBC Capital
Henkel price target raised to EUR 99 from EUR 98 at RBC Capital
08/18/20 Barclays
Henkel price target raised to EUR 89 from EUR 88 at Barclays
08/11/20 Berenberg
Henkel price target raised to EUR 85 from EUR 84 at Berenberg
HENKY Henkel
$0.00 /

+ (+0.00%)

Upgrade
L'Oreal upgraded to Buy from Neutral at Goldman Sachs » 19:40
09/28/20
09/28
19:40
09/28/20
19:40
LRLCY

L'Oreal

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LRLCY L'Oreal
$0.00 /

+ (+0.00%)

LRLCY L'Oreal
$0.00 /

+ (+0.00%)

09/17/20 Bryan Garnier
L'Oreal upgraded to Conviction Buy from Neutral at Bryan Garnier
08/20/20 Argus
L'Oreal price target raised to $76 from $68 at Argus
08/18/20 Barclays
L'Oreal price target raised to EUR 250 from EUR 236 at Barclays
08/18/20 RBC Capital
Estee Lauder price target raised to $194 from $173 at RBC Capital
LRLCY L'Oreal
$0.00 /

+ (+0.00%)

LRLCY L'Oreal
$0.00 /

+ (+0.00%)

Hot Stocks
Apollo Endosurgery discontinues furlough program » 19:34
09/28/20
09/28
19:34
09/28/20
19:34
APEN

Apollo Endosurgery

$1.38 /

-0.04 (-2.82%)

On September 23, 2020,…

On September 23, 2020, the company discontinued the employee furlough program previously announced on its Current Report on Form 8-K, filed with the SEC on April 20, 2020. Of the U.S.-based employees originally placed on furlough, 35 employees will not be recalled. The normalized annual compensation costs associated with these positions prior to previously announced compensation reductions due to the COVID-19 pandemic were approximately $5.0M. Total severance costs in the third quarter of 2020 are expected to be approximately $0.2M to $0.3M.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

Earnings
Apollo Endosurgery sees Q3 revenue above Q3 of last year » 19:32
09/28/20
09/28
19:32
09/28/20
19:32
APEN

Apollo Endosurgery

$1.38 /

-0.04 (-2.82%)

In a regulatory 8K filing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

APEN Apollo Endosurgery
$1.38 /

-0.04 (-2.82%)

04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
11/18/19 Piper Sandler
Apollo Endosurgery transferred with an Overweight rating at Piper Jaffray
Hot Stocks
Ascendis Pharma announces 6-month data from ph.2 study of TransCon PTH » 19:07
09/28/20
09/28
19:07
09/28/20
19:07
ASND

Ascendis Pharma

$151.83 /

-2.2 (-1.43%)

Ascendis Pharma announced…

Ascendis Pharma announced preliminary six-month results from the open-label extension portion of PaTH Forward, a global phase 2 trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism, or HP. Preliminary six-month results from the PaTH Forward OLE demonstrated: 91% of all subjects eliminated standard of care, including 76% who eliminated all supplements. 86% of all subjects normalized or reduced by 50% 24-hour urine calcium. 71% of all subjects achieved a response on the composite endpoint of (1) serum calcium in the normal range, (2) independence from active vitamin D, (3) taking less than or equal to500 mg/day of calcium supplements, and (4) 24-hour urine calcium in the normal range or 50% reduction from baseline, including 74% of subjects who were randomized to TransCon PTH. The company submitted an amendment to its investigational new drug application with the FDA to initiate the U.S. sites of the PaTHway phase 3 clinical trial evaluating the safety, tolerability and efficacy of TransCon PTH in adults with HP following discussions with FDA and European regulatory authorities. The company expects to file the clinical trial application for the European arm later this year. The double-blind, placebo-controlled trial is expected to enroll approximately 76 subjects at sites in North America and Europe in order to obtain 68 evaluable subjects.

ShowHide Related Items >><<
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

09/14/20 JPMorgan
Ascendis Pharma resumed with an Overweight at JPMorgan
08/31/20 Cantor Fitzgerald
Cantor says Ascendis has important catalyst coming with TransCon PTH data
05/20/20 Credit Suisse
Ascendis Pharma price target raised to $154 from $149 at Credit Suisse
05/20/20 Oppenheimer
Ascendis Pharma price target lowered to $208 from $219 at Oppenheimer
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

  • 08
    Jul
ASND Ascendis Pharma
$151.83 /

-2.2 (-1.43%)

General News
Pelosi says Democrats introducing new COVID-19 relief package » 18:59
09/28/20
09/28
18:59
09/28/20
18:59
SPY

SPDR S&P 500 ETF Trust

$334.20 /

+5.51 (+1.68%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

According to a statement…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

09/01/20
Fed's Brainard says monetary policy to pivot from stabilization to accommodation
08/17/20 Goldman Sachs
Goldman boosts end of 2020 S&P 500 target to 3,600 from 3,000
06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$334.20 /

+5.51 (+1.68%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Hot Stocks
Boeing awarded $249M Missile Defense Agency contract modification » 18:35
09/28/20
09/28
18:35
09/28/20
18:35
BA

Boeing

$166.20 /

+10.13 (+6.49%)

Boeing was awarded a…

Boeing was awarded a $249M undefinitized contract modification to a previously awarded on the Ground-based Midcourse Defense Development and Sustainment contract, or DSC. The scope of work under the current DSC includes development, fielding, test, systems engineering, integration and configuration management, equipment manufacturing and refurbishment, training and operations and sustainment for the GMD weapon system and associated support facilities. Under this undefinitized modification, the Missile Defense Agency executes the Service Life Extension Program, or SLEP, upgrade of ground based interceptors, or GBI; the upgrade and repair of specialized production equipment necessary to support SLEP activities; systems engineering to support CE-I fleet readiness; cybersecurity activities and the production of a payload to support system testing requirements. The value of this contract, including options, is increased from $11.52B to $11.77B. The period of performance is from September 24 to December 31, 2022. This acquisition was executed on a sole-source basis. FY20 research, development, test and evaluation funds in the amount of $45.69M have been obligated at the time of award. The Missile Defense Agency is the contracting activity.

ShowHide Related Items >><<
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

09:53 Today
Fly Intel: Top five analyst upgrades
08:46 Today Alembic Global
Alembic upgrades Boeing with 737 MAX return 'finally in sight'
08:27 Today Alembic Global
Boeing upgraded to Overweight from Neutral at Alembic Global
09/24/20 Wolfe Research
Boeing upgraded to Peer Perform from Underperform at Wolfe Research
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

Hot Stocks
Cable One to acquire 45% minority stake in MBI for about $574.1M in cash » 18:32
09/28/20
09/28
18:32
09/28/20
18:32
CABO

Cable One

$1,755.00 /

+24.06 (+1.39%)

Mega Broadband…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

08/11/20 Truist
Cable One price target raised to $2,000 from $1,850 at Truist
05/12/20 KeyBanc
Cable One price target raised to $2,105 from $1,968 at KeyBanc
05/12/20 Truist
Cable One price target raised to $1,850 from $1,600 at SunTrust
04/20/20 Cowen
Cable One initiated with a Market Perform at Cowen
CABO Cable One
$1,755.00 /

+24.06 (+1.39%)

  • 20
    May
Hot Stocks
Honeywell awarded $258.66M Army contract » 18:31
09/28/20
09/28
18:31
09/28/20
18:31
HON

Honeywell

$164.42 /

+2.87 (+1.78%)

Honeywell was awarded a…

Honeywell was awarded a $258.66M firm-fixed-price contract for overhaul/repair of T55-GA-714A engines for the CH-47 Chinook. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of July 31, 2021. The U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
07/28/20 Argus
Honeywell price target raised to $165 at Argus on continued product diversity
07/27/20 JPMorgan
Honeywell price target raised to $185 from $177 at JPMorgan
HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

HON Honeywell
$164.42 /

+2.87 (+1.78%)

Hot Stocks
Raytheon Technologies awarded $398.33M Army contract modification » 18:29
09/28/20
09/28
18:29
09/28/20
18:29
RTX

Raytheon Technologies

$58.90 /

+1.41 (+2.45%)

Raytheon Technologies was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

09/20/20 Goldman Sachs
Lockheed Martin downgraded to Buy from Conviction Buy at Goldman Sachs
09/20/20 Goldman Sachs
Raytheon upgraded to Conviction Buy from Buy at Goldman Sachs
09/08/20 Morgan Stanley
Raytheon Technologies initiated with an Overweight at Morgan Stanley
07/29/20 Argus
Raytheon Technologies downgraded to Hold from Buy at Argus
RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

RTX Raytheon Technologies
$58.90 /

+1.41 (+2.45%)

On The Fly
Fly Intel: After-Hours Movers » 18:27
09/28/20
09/28
18:27
09/28/20
18:27
FLUX

Flux Power

$5.45 /

+0.05 (+0.93%)

, RLGT

Radiant Logistics

$5.23 /

+0.16 (+3.16%)

, DNLI

Denali Therapeutics

$35.27 /

+0.14 (+0.40%)

, DYN

Dyne Therapeutics

$21.49 /

-0.52 (-2.36%)

, SNOW

Snowflake

$250.29 /

+21.06 (+9.19%)

, UNFI

United Natural Foods

$19.13 /

+1.235 (+6.90%)

, BEAM

Beam Therapeutics

$26.87 /

+0.14 (+0.52%)

Check out this evening's…

ShowHide Related Items >><<
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

05/12/20 Lake Street
Radiant Logistics price target lowered to $7 from $9 at Lake Street
02/28/20 Benchmark
Radiant Logistics initiated with a Buy at Benchmark
DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

09/14/20 JPMorgan
Denali Therapeutics resumed with an Overweight at JPMorgan
08/20/20 H.C. Wainwright
Denali Therapeutics price target raised to $45 from $28 at H.C. Wainwright
08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20
Snowflake initiated with a Sell at Summit Insights
09/21/20 Summit Insights
Snowflake initiated with a Sell at Summit Insights
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

09/23/20 Northcoast
United Natural Foods upgraded to Buy from Neutral at Northcoast
07/30/20 MKM Partners
United Natural Foods initiated with a Buy at MKM Partners
07/29/20 MKM Partners
United Natural Foods initiated with a Buy at MKM Partners
07/16/20 BTIG
United Natural Foods initiated with a Neutral at BTIG
BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 William Blair
Beam Therapeutics initiated with an Outperform at William Blair
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

RLGT Radiant Logistics
$5.23 /

+0.16 (+3.16%)

FLUX Flux Power
$5.45 /

+0.05 (+0.93%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

  • 01
    Oct
  • 17
    Sep
  • 16
    Sep
  • 29
    Jan
  • 06
    Feb
SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

BEAM Beam Therapeutics
$26.87 /

+0.14 (+0.52%)

UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

DYN Dyne Therapeutics
$21.49 /

-0.52 (-2.36%)

DNLI Denali Therapeutics
$35.27 /

+0.14 (+0.40%)

UNFI United Natural Foods
$19.13 /

+1.235 (+6.90%)

SNOW Snowflake
$250.29 /

+21.06 (+9.19%)

Hot Stocks
General Dynamics awarded $215.66M Navy contract modification » 18:27
09/28/20
09/28
18:27
09/28/20
18:27
GD

General Dynamics

$140.76 /

+2.495 (+1.80%)

General Dynamics was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GD General Dynamics
$140.76 /

+2.495 (+1.80%)

GD General Dynamics
$140.76 /

+2.495 (+1.80%)

09/17/20
Fly Intel: Top five analyst downgrades
09/17/20 Goldman Sachs
General Dynamics downgraded to Sell from Buy at Goldman Sachs
09/08/20 Morgan Stanley
General Dynamics initiated with an Underweight at Morgan Stanley
08/03/20
Fly Intel: Top five analyst downgrades
GD General Dynamics
$140.76 /

+2.495 (+1.80%)

GD General Dynamics
$140.76 /

+2.495 (+1.80%)

GD General Dynamics
$140.76 /

+2.495 (+1.80%)

GD General Dynamics
$140.76 /

+2.495 (+1.80%)

Hot Stocks
Lockheed Martin awarded $709.79M Navy contract modification » 18:24
09/28/20
09/28
18:24
09/28/20
18:24
LMT

Lockheed Martin

$390.46 /

+3.6 (+0.93%)

Lockheed Martin was…

Lockheed Martin was awarded a $709.79M modification to a previously awarded fixed-price-incentive-firm-target advance acquisition contract. This modification provides for the procurement of economic order quantities of material in support of F-35 Lightning II aircraft low rate initial production Lots 15, 16 and 17 for the Air Force, Marine Corps, Navy, non-Department of Defense, or DoD, participants and foreign military sales, or FMS, customers. Work is expected to be completed in May 2026. FY20 aircraft procurement funds in the amount of $260.38M; FY20 aircraft procurement funds in the amount of $245.41M; non-DoD participant funds in the amount of $141.76M and FMS funds in the amount of $62.24M, will be obligated at time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

ShowHide Related Items >><<
LMT Lockheed Martin
$390.46 /

+3.6 (+0.93%)

LMT Lockheed Martin
$390.46 /

+3.6 (+0.93%)

09/20/20 Goldman Sachs
Lockheed Martin downgraded to Buy from Conviction Buy at Goldman Sachs
09/08/20 Morgan Stanley
Lockheed Martin initiated with an Overweight at Morgan Stanley
07/24/20 Argus
Lockheed Martin price target raised to $450 from $425 at Argus
07/17/20 RBC Capital
Lockheed Martin price target lowered to $404 from $410 at RBC Capital
LMT Lockheed Martin
$390.46 /

+3.6 (+0.93%)

LMT Lockheed Martin
$390.46 /

+3.6 (+0.93%)

LMT Lockheed Martin
$390.46 /

+3.6 (+0.93%)

Hot Stocks
Quidel supports Trump administration's plans for school COVID-19 testing » 18:13
09/28/20
09/28
18:13
09/28/20
18:13
QDEL

Quidel

$198.32 /

+1.28 (+0.65%)

, ABT

Abbott

$104.48 /

+1.04 (+1.01%)

Quidel Corporation (QDEL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
QDEL Quidel
$198.32 /

+1.28 (+0.65%)

ABT Abbott
$104.48 /

+1.04 (+1.01%)

QDEL Quidel
$198.32 /

+1.28 (+0.65%)

08/28/20 Piper Sandler
COVID-19 test provider selloff on Abbott approval overdone, says Piper
08/28/20 Piper Sandler
Quidel pullback on Abbott approval a buying opportunity, says Piper Sandler
08/27/20 Piper Sandler
Piper says medical diagnostics stocks oversold on Abbott COVID-19 test news
08/27/20 Goldman Sachs
Abbott test's sensitivity, low price 'positive surprises,' says Goldman Sachs
ABT Abbott
$104.48 /

+1.04 (+1.01%)

13:34 Today Stifel
Libre 3 CE Mark approval a 'positive surprise' for Abbott, says Stifel
10:51 Today Piper Sandler
Piper says DexCom's coming G7 introduction important as Abbott narrows gap
09/11/20 Wolfe Research
Abbott initiated with an Outperform at Wolfe Research
08/31/20 Credit Suisse
Abbott price target raised to $136 from $109 at Credit Suisse
QDEL Quidel
$198.32 /

+1.28 (+0.65%)

ABT Abbott
$104.48 /

+1.04 (+1.01%)

QDEL Quidel
$198.32 /

+1.28 (+0.65%)

ABT Abbott
$104.48 /

+1.04 (+1.01%)

QDEL Quidel
$198.32 /

+1.28 (+0.65%)

ABT Abbott
$104.48 /

+1.04 (+1.01%)

ABT Abbott
$104.48 /

+1.04 (+1.01%)

Hot Stocks
Maxeon Solar files patent infringement suit against Canadian Solar in Japan » 18:08
09/28/20
09/28
18:08
09/28/20
18:08
MAXN

Maxeon Solar

$16.18 /

+1.91 (+13.38%)

, CSIQ

Canadian Solar

$34.01 /

+1.82 (+5.65%)

Maxeon Solar (MAXN)…

Maxeon Solar (MAXN) announced that it filed a patent infringement lawsuit against Canadian Solar Japan K.K., in Tokyo District Court, Japan. The lawsuit filing alleges Canadian Solar Japan infringes Maxeon's Japan Patent No. JP6642841B2 for the proprietary and fundamental shingled solar cell panel technology used to deploy solar panels that Maxeon designs, manufactures and sells under the 'SunPower Performance' brand name. Canadian Solar Japan is a wholly owned subsidiary of Canadian Solar (CSIQ), which is headquartered in Canada with operations and production facilities in China and in South-East Asia.

ShowHide Related Items >><<
MAXN Maxeon Solar
$16.18 /

+1.91 (+13.38%)

CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

MAXN Maxeon Solar
$16.18 /

+1.91 (+13.38%)

09/11/20 Baird
Baird upgrades 'simpler' SunPower to Outperform with $13 target
09/03/20 Raymond James
Maxeon Solar initiated with a Market Perform at Raymond James
08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Goldman Sachs
Maxeon Solar initiated with a Neutral at Goldman Sachs
CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

08/27/20 GLJ Research
Canadian Solar initiated with a Strong Buy at GLJ Research
07/20/20 Roth Capital
Roth boosts Daqo target to $120 after polysilicon facility explosion reports
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

MAXN Maxeon Solar
$16.18 /

+1.91 (+13.38%)

CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

MAXN Maxeon Solar
$16.18 /

+1.91 (+13.38%)

CSIQ Canadian Solar
$34.01 /

+1.82 (+5.65%)

Periodicals
House lawmakers unveil plan to revise FAA jet approvals, Bloomberg reports » 17:55
09/28/20
09/28
17:55
09/28/20
17:55
BA

Boeing

$166.20 /

+10.13 (+6.49%)

A bipartisan bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

09:53 Today
Fly Intel: Top five analyst upgrades
08:46 Today Alembic Global
Alembic upgrades Boeing with 737 MAX return 'finally in sight'
08:27 Today Alembic Global
Boeing upgraded to Overweight from Neutral at Alembic Global
09/24/20 Wolfe Research
Boeing upgraded to Peer Perform from Underperform at Wolfe Research
BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

BA Boeing
$166.20 /

+10.13 (+6.49%)

Periodicals
Petrobras plans to spend $6B through 2024 to decommission assets, Reuters says » 17:46
09/28/20
09/28
17:46
09/28/20
17:46
PBR

Petrobras

$7.20 /

-0.26 (-3.49%)

Petrobras said it intends…

Petrobras said it intends to spend $6B through 2024 to decommission 18 offshore platforms, underwater gas pipelines, and offshore wells, Reuters' Sabrina Valle reports. In a presentation filed to the securities regulator, Brazil's state-controlled oil producer said it anticipates proceeds of $1B from divestments in 2020, after receiving $14.4B from asset sales last year, Valle notes. Reference Link

ShowHide Related Items >><<
PBR Petrobras
$7.20 /

-0.26 (-3.49%)

PBR Petrobras
$7.20 /

-0.26 (-3.49%)

05/18/20 Raymond James
Petrobras downgraded to Underperform from Market Perform at Raymond James
05/18/20 Raymond James
Petrobras downgraded to Underperform from Market Perform at Raymond James
05/14/20 BofA
Petrobras downgraded to Neutral from Buy at BofA
05/08/20 Bradesco BBI
Petrobras upgraded to Outperform from Neutral at Bradesco
  • 06
    Feb
PBR Petrobras
$7.20 /

-0.26 (-3.49%)

PBR Petrobras
$7.20 /

-0.26 (-3.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.